FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)													
Name and Address of Reporting Person* Wendel Bruce				2. Issuer Name and Ticker or Trading Symbol GT Biopharma, Inc. [GTBP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O GT BIOPHARMA, INC., 8000 MARINA BLVD., SUITE 100				3. Date of Earliest Transaction (Month/Day/Year) 07/15/2022						Officer (give	title below)	Other	(specify below)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
BRISBAI (City	NE, CA 94	(State)	(Zip)												
		(State)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			Execution Date, if C		Code	Fransaction de (A) or Disposed o (Instr. 3, 4 and 5)		(D) Own Tran	Owned Following Reported Ownership of Form: B (Instr. 3 and 4) Direct (D)		. Nature f Indirect geneficial Ownership Instr. 4)				
		Code V Amount (A) or (D) Price			(I) (Instr. 4)										
Reminder: F	Report on a se	eparate line for each	class of securities be	eneficiall	ly ov	vned direc	etly o	or indirectly.							
								in this fo	who respond rm are not re ly valid OMB	quired to	respond ι				74 (9-02)
			Table II ·						ed of, or Benefi vertible securit		ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Option to purchase Common Stock	\$ 2.48	07/15/2022		A		50,000		07/15/2022	07/14/2032	Commo Stock	n 50,000	\$ 0	50,000	D	
Option to purchase Common Stock	\$ 2.48	07/15/2022		A		50,000		(1)	07/14/2032	Commo Stock	n 50,000	\$ 0	50,000	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Wendel Bruce C/O GT BIOPHARMA, INC. 8000 MARINA BLVD., SUITE 100 BRISBANE, CA 94005	X					

Signatures

/s/ Bruce Wendel	07/19/2022			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- $\textbf{(1)} \ \ 1/4 th \ of the \ shares \ vest \ on \ the \ date \ of \ grant \ and \ on \ each \ of \ September \ 8, 2022, \ December \ 8, 2022 \ and \ March \ 8, 2023.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.